| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action agonists | 
| Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CD276 agonists(CD276 antigen agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | Egypt  | 18 Oct 2024 | |
| Neoplasms | Preclinical | United States  | 18 Oct 2024 | 





